Vulgaroo simplifie les comptes-rendus médicaux pour les rendre compréhensibles par les patients.
Vulgaroo simplifie les comptes-rendus médicaux pour les rendre compréhensibles par les patients.
Deeptech française spécialisée dans l’analyse du microbiome cutané, du cuir chevelu, oral et vaginal pour accompagner les marques dans la valorisation de l’impact microbiome de leurs produits.
StemInov développe une plateforme de thérapie cellulaire innovante utilisant des cellules souches mésenchymateuses issues du cordon ombilical, prometteuses pour traiter les complications des pneumonies sévère
AUSTRAL Dx is developing a new way to diagnose cardiac and pulmonary diseases to unclog ER dpt with airborne ultrasound.
Une solution logicielle B2B de digitalisation 3D du corps humain via mobile pour la MedTech
an innovative start-up that is transforming the pharmaceutical industry by enabling pharmacies to manufacture personalised medicines using 3D printing
Sirius NeoSight is an innovative disruptive technology company for the detection of sub-clinical neo-cancers, relapses and the therapeutic follow-up of patients.
HuntX Pharma is developing small oral molecules to prevent the onset of genetic neurodegenerative diseases.
Abcely develops innovative medical and pharmaceutical technologies for the treatment of mucosal cancers.
Alga Therpeutics produces cancer-fighting antibodies from micro-algae.
Odimma develops personalized immunotherapy using AI and synthetic DNA technology.
Kimialys offers an innovative, patented chemical coating that improves the reliability of diagnostic tests.
Hephaistos-Pharma is developing a new generation of immunostimulant to treat metastatic and hardly accessible tumors
Healshape is developing a personalized, natural, regenerative and resorbable bioprosthesis for women who have undergone a mastectomy following breast cancer.
"We believe that when it comes to seed financing in the healthcare sector, an innovative start-up can effectively benefit from the support of such a specialized investor, as they understand the specificity of our business model much better than generalist business angels or family office and they are more flexible than life science VCs."
"Angels Santé, in addition to other investors, has given Abcely credibility for its project in the eyes of other, more generalist co-investors, less able to appreciate the real challenges that can be encountered by a biotech company in the healthcare field, more specifically in oncology."
"Angel Santé gives you access to a network of professional investors in the healthcare sector who are keen to get involved in your company's development. Beyond financing, you gain access to invaluable skills in a sector of expertise."
The club offers quarterly physical meetings, co-hosted by entrepreneurs themselves. You benefit from their feedback on a specific theme.
Sessions are co-hosted by other speakers (associate corporate members, ecosystem players, etc.) sharing their expertise.
